Introduction
============

Subsequent to the pioneering original synthesis of oxytocin (OT) ([@b2]) and arginine vasopressin (AVP) ([@b3]) by Vincent du Vigneaud and his associates, thousands of analogues of both of these neurohypophysial peptides have been synthesised in many laboratories throughout the world. The Merrifield solid phase method ([@b4]) has been of inestimable importance in facilitating the rapid and efficient synthesis of agonists and antagonists for the AVP V~1a~, V~1b~ and V~2~ receptors and for the OT uterine receptor ([@b5]). Many of these ligands have found widespread use as pharmacological tools for studies on the peripheral and central effects of OT and AVP. These design and synthetic studies have been the subject of numerous reviews ([@b1; @b6; @b7; @b8; @b9; @b10; @b11; @b12; @b13; @b14; @b15; @b16; @b17; @b18; @b19; @b20]).

Structure activity and design studies carried out in other laboratories over the past five decades have laid the foundation for the design studies that we present here. These pivotal contributions by others have been fully documented ([@b11], [@b14], [@b18], [@b20]).

Oxytocin and AVP mediate their biological effects by acting on specific receptors ([@b21; @b22; @b23]). OT and AVP receptors belong to a G-protein coupled receptor family, characterised by seven putative transmembrane helices. Reviews on AVP and OT receptors are available elsewhere ([@b12], [@b22], [@b23]). OT receptors are expressed in the uterus, the mammary gland, the ovary, the brain, the kidney, the heart, bone and in endothelial cells ([@b23]). In the uterus, OT receptors mediate the uterine contracting (oxytocic) effect of OT ([@b23]). The central effects of OT continue to be the focus of intense investigative scrutiny in animals ([@b24; @b25; @b26; @b27; @b28]) and in humans ([@b29; @b30; @b31; @b32; @b33; @b34; @b35]), as a possible therapeutic agent for the treatment of autism and other anxiety disorders.

Arginine vasopressin mediates its actions through three known receptors: V~1a~, V~1b~ and V~2~. V~1a~ receptors are expressed in the liver, vascular smooth muscle cells, brain and in many other tissues ([@b12], [@b21], [@b22]). In the vasculature, V~1a~ receptors mediate the pressor actions of AVP by a phospholipase C-mediated pathway. In the brain, V~1a~ receptors mediate the anxiety producing responses to AVP ([@b27], [@b36]). V~1b~ receptors, discovered long after the V~1a~ and V~2~ receptors, present in the anterior pituitary, mediate the adrenocorticotrophic hormone-releasing effects of AVP, also by a phospholipase C-mediated pathway ([@b22]) Evidence for the presence of V~1b~ receptors in extra-pituitary tissues such as brain, the kidney and the adrenal medulla has also been reported ([@b37]). Recently, the V~1b~ receptor has been shown to mediate anxiety and stress in rats and in humans ([@b45]). V~2~ receptors, present in the collecting duct of the kidney, mediate the antidiuretic action of AVP by an adenylate cyclase-mediated pathway ([@b12], [@b21], [@b22]).

Scope of the present review
===========================

We have previously reviewed the status of developments in the design and synthesis of peptide and nonpeptide AVP and OT agonists and antagonists ([@b1]). Here, we focus on the properties of the most widely used peptides requested from the Manning laboratory or purchased from suppliers, together with some recently reported potential clinically useful peptides from the Ferring Laboratory ([@b38], [@b39]). Space considerations preclude our being able to present or to discuss recent synthetic studies carried out in other laboratories ([@b40; @b41; @b42; @b43]). We also update the current status of the pre-clinical and clinical development of nonpeptide AVP and OT antagonists and of the pre-clinical development of nonpeptide OT agonists ([@b44]). The excellent reviews on nonpeptide AVP antagonists ([@b45]) and on nonpeptide OT antagonists ([@b46]) should be consulted for more in-depth presentations of their chemistry and pharmacology. We also review the merits of peptide versus nonpeptide AVP and OT agonists and antagonists as: (i) research tools and (ii) therapeutic agents. We present human and rat receptor data for a number of selective peptide agonists and for both peptide and nonpeptide antagonists. We illustrate the need to be aware of: (i) species differences, (ii) selectivity differences and (iii) *in vitro--in vivo* differences when using a specific ligand for receptor characterisation. Finally, we present the highlights of our recent studies aimed at: (i) the development of selective fluorescent ligands for the rat and human V~1b~ receptors ([@b47]) and (ii) the development of fluorescence based strategies that have been used to prove the existence of OT receptor dimers in native tissue ([@b48]).

Peptide synthesis
=================

All the OT and AVP agonists, antagonists, radiolabelled and fluorescent ligands from our laboratories were synthesised using the Merrifield solid-phase method ([@b4], [@b49]). The synthetic strategy relies very heavily on methodology developed in the du Vigneaud laboratory for the original syntheses of OT and AVP ([@b2], [@b3]). The procedures used are described in the original publications cited here. For other references, see Manning *et al.* ([@b1]).

Bioassays
=========

All of the published peptides from our laboratories, presented in [Tables 1](#tbl1){ref-type="table"}, [3](#tbl3){ref-type="table"}--[8](#tbl8){ref-type="table"}, were assayed for agonistic and antagonistic activities in *in vitro* and *in vivo* rat oxytocic assays, in the rat vasopressor assay and in the rat antidiuretic assay in the laboratories of our collaborators Drs Wilbur H. Sawyer, W. Y. Chan and Hazel Szeto. For agonists, the four-point assay design ([@b50]) was used and for antagonists, Schild's pA~2~ method ([@b51]) was employed. The pA~2~ is the negative logarithm of the molar concentration of the antagonist that requires a two-fold increase in agonist concentration to achieve the same effect as that found in the absence of antagonist. In practice, this concentration is estimated by finding concentrations above and below the pA~2~ dose and interpolating on a logarithmic scale.

In the rat *in vivo* assays, the pA~2~ (effective dose) is divided by an arbitrarily assumed volume of distribution of 67 ml/kg ([@b52]) in an attempt to derive the approximate molar concentration \[M\] of the pA~2~ dose in the vicinity of the receptors. Thus, *in vivo* pA~2~ values are very approximate estimates. The USP Posterior Pituitary Reference Standard or synthetic OT and AVP, which had been standardised in oxytocic and vasopressor units against this standard, were used as agonists for working standards in all bioassays. *In vitro* oxytocic assays were performed on isolated uteri from diethylstilbestrol-primed rats in a Mg^2+^-free van Dyke Hasting's solution ([@b53]). *In vivo* anti-OT potencies were determined in urethane-anaesthetised diethylstilbestrol-primed rats as described previously ([@b54], [@b55]). Vasopressor assays were performed on urethane-anaesthetised and phenoxybenzamine-treated rats as described by Dekanski ([@b55]), and antidiuretic assays on water-loaded rats under ethanol anesthesia as described by Sawyer ([@b56]).

Receptor binding and functional assays
======================================

Membranes and/or cell lines that express the rat and human AVP V~1a~, V~1b~ and V~2~ receptors ([@b57; @b58; @b59; @b60; @b61; @b62; @b63; @b64]) and the human OT receptor ([@b65]) were used for binding and functional assays: inositol phosphate accumulation ([@b66]) for V~1a~, V~1b~ and OT receptors and cyclic AMP accumulation ([@b67]) for V~2~ receptors, as described previously ([@b68; @b69; @b70; @b71; @b72; @b73; @b74]). These receptor studies were carried out in Montpellier and Milan.

Selective oxytocin agonists ([Table 1](#tbl1){ref-type="table"})
================================================================

###### 

Potent and Selective Agonists for the Uterine Oxytocin Receptor in the Rat.

                                                                             Ratios              
  --- -------------------------------------------- ------ --------- -------- -------- ---------- ----
      OT                                           520    4         4        130      130        75
  1   \[Thr^4^\]OT                                 923    0.4       0.9      1025     2307       75
  2   HO\[Thr^4^\]OT                               4179   4.92      5.3      790      850        75
  3   \[Thr^4^, Gly^7^\]OT                         166    \< 0.01   ∼0.002   83 000   \>16 600   75
  4   HO\[Thr^4^, Gly^7^\]OT                       218    \< 0.01   0.004    54 500   \>21 800   75
  5   Carba-1-\[4-FBzlGly^7^\]dOT(FE 202767)^\*^   ND     ND        ND                           38

OT, oxytocin; HO, 1-hydroxy (hydroxyl group replaces α-amino group); FBzl, fluorobenzyl. *^\*^In vitro* potency EC~50~^a^ (n[m]{.smallcaps}) hOT 0.08, hV~2~ 330, hV~1a~\>10000 selectivity versus receptor hV~2~ 4100, hV~1b~ \> 120000. ^a^EC~50~ is the concentration of agonist leading to half-maximal activity. ND, Not determined.

The pharmacological properties in rat bioassays for OT and the four analogues (peptides **1**--**4**), which are more potent and/or more selective than OT ([@b75]), are given in [Table 1](#tbl1){ref-type="table"}. \[Thr^4^,Gly^7^\]OT (peptide **3**), also referred to as TGOT, has been widely used as a selective OT agonist. Its human and rat receptor affinities are given in [Table 11](#tbl11){ref-type="table"}. The recently reported ([@b38]) highly selective OT analogue FE 202767 (peptide **5**) has not been evaluated in standard rat bioassays. It exhibits high affinity and selectivity for the human OT receptor. It thus offers promise as a potential new OT therapeutic ([@b38]).

The two new OT-related analogues given in [Table 2](#tbl2){ref-type="table"} ([@b1], [@b2]) have not yet been evaluated in standard rat bioassays. The discovery of \[Pro^8^\]OT in new world monkeys by Lee *et al*. ([@b76]), independently confirmed by Jeffrey French and colleague (E. B. Harrison and J. A. French, personal communication), is an exciting new development in this field. The novel C-terminal extended analogue of OT; oxytocin-Gly-Lys-Arg, reported by Gutkowska *et al*. ([@b77]) and Danalache *et al*. ([@b78]), opens up new possibilities for the design of potential new cardiomyogenic therapies.

###### 

New Oxytocin (OT)-Related Peptides.

  Number   Peptide                Reference
  -------- ---------------------- -----------
  1        Oxytocin-Gly-Lys-Arg   77, 78
  2        \[Pro^8^\]OT           76

Selective vasopressin V~2~ receptor agonists ([Table 3](#tbl3){ref-type="table"})
=================================================================================

###### 

Potent and Selective Agonists for the Vasopressin V~2~ Receptor in the Rat^a^.

                                                                           Ratios             
  --- -------------------------- ------ --------------------------- ------ ---------- ------- --------
      AVP                        14     373                         320    0.9        22.8    79
  1   dDAVP (desmopressin)^\*^   1.5    0.39                        1200   3000       800     79, 80
  2   VDAVP                      0.60   0.037                       653    17 650     1 090   79
  3   dVDAVP                     8      Antagonist (pA~2~ = 7.03)   1230   Infinite           79

OT, oxytocin; AVP, arginine vasopressin; d, 1-deamino; DAVP, D-Arg^8^VP; V, Val^4^. ^\*^Desmopressin is the drug of choice for the treatment of diabetes insipidus. ^a^The data given are obtained from Sawyer *et al.* (79).

AVP is equipotent as an antidiuretic agonist and as a vasopressor agonist ([@b79]) ([Table 3](#tbl3){ref-type="table"}). Thus, it is totally nonselective. It is also not selective with respect to its oxytocic activity. The three analogues of AVP, peptides **1**--**3** in [Table 3](#tbl3){ref-type="table"} namely; dDAVP, VDAVP and dVDAVP, exhibit striking gains in antidiuretic/vasopressor selectivity. All three peptides have been widely used as selective V~2~ agonists. dDAVP, first synthesised by the Zaoral *et al*. ([@b80]) in Prague and later licensed to Ferring, has long been the drug of choice for the treatment of diabetes insipidus. It has been marketed under the trademark Desmopressin (Minirin). The human receptor affinities for dDAVP and dVDAVP given in [Table 11](#tbl11){ref-type="table"} shows clearly that dVDAVP has a ten-fold higher affinity for the human VP V~2~ receptor than dDAVP. However, both peptides also exhibit high affinities for the human V~1b~ receptor and to somewhat lesser extent for the human OT receptor ([Table 11](#tbl11){ref-type="table"}). So clearly they are not selective V~2~ agonists in humans with respect to both hV~1b~ or hV~1a~ receptors. The search for a V~2~ agonist that is selective with respect to the V~1a~ and V~1b~ receptors in humans is still a challenging goal in this field. Yet, in the rat, dDAVP could be considered as a relatively good selective V~2~ agonist ([Table 11](#tbl11){ref-type="table"}).

Selective vasopressin V~1a~ receptor agonists ([Table 4](#tbl4){ref-type="table"})
==================================================================================

###### 

Potent and Selective Agonists for the Vasopressin V~1a~ Receptor in the Rat.

                                                                     Ratios          
  --- ------------------------------------------- ----- ------ ----- -------- ------ --------
      AVP                                         373   320    14    1.2      26.6   79, 84
      LVP (\[Lys^8^\]VP)                          270   284    10    0.95     27     85
  1   \[Phe^2^\]LVP (felypressin, octapressin)    57    21     0.3   2.7      190    17
  2   \[Phe^2^\]OVT, \[Phe^2^,Orn^8^\]vasotocin   124   0.55   1     225      124    81
  3   F-180                                       164   0.19         863             82
  4   FE 202158^\*^                               ND    ND     ND                    39, 83

OT, oxytocin; F180, Hmp-Phe-Ile-Hgn-Asn-Cys-Pro-Dab(Abu)-Gly-NH~2~; where Hmp, 2-hydroxy-3-mercaptopropionic acid; Hgn, homoglutamine; Dab, 2,4-diaminobutyric acid; Abu, 2-aminobutyric acid; ^\*^FE 202158, \[Phe^2^,Ile^3^,Hgn^4^,Orn(iPr)^8^\]AVP, where Hgn is homoglutamine and iPr is isopropyl.

In rat bioassays, \[Phe^2^\]OVT (peptide **2**; [Table 4](#tbl4){ref-type="table"}) is a fairly potent vasopressor agonist ([@b81]). Its vasopressor (P) activity is 124 units/mg. In antidiuretic (A) assays, it exhibits only 0.55 units/mg. Its P/A ratio is 225 ([@b81]). Thus, for many years, it has been considered to be a selective V~1a~ agonist and has been widely used as a selective V~1a~ agonist. However, based on its rat V~1a~ receptor affinity data in [Table 11](#tbl11){ref-type="table"}, it is not selective for the rat V~1a~ receptor in this assay. In this regard, the selective V~1a~ agonist F-180 ([@b82]), which is a highly selective V~1a~ agonist in rat bioassays (peptide **3**; [Table 4](#tbl4){ref-type="table"}), is even more puzzling. In rat receptor assays ([Table 11](#tbl11){ref-type="table"}), it is clearly nonselective for V~1a~ receptors. By contrast, F-180 exhibits high affinity and selectivity for the human V~1a~ receptor. The exciting new V~1a~ agonist (peptide **4**; [Table 5](#tbl5){ref-type="table"}), FE202158, recently reported by Ferring ([@b39], [@b83]) is currently undergoing clinical trials for the treatment of vasodilating hypotension. Compared to F180, this peptide exhibits better selectivity for the human V~1a~ receptor ([Table 11](#tbl11){ref-type="table"}). In the rat, this agonist is very specific for the V~1a~ receptor compared to the V~2~ receptor (selectivity higher than 800), yet it has not been tested for the OT and V~1b~ receptors. This intriguing new V~1a~ agonist is not yet available to other scientists for use as a pharmacological research tool.

###### 

Lys^8^ Analogues of d\[Cha^4^\]AVP ([@b1]) and d\[Leu^4^\]AVP ([@b3]) exhibit High Affinities and Selectivities for both Rat and Human V~1b~ Receptors.

                                      Affinity (K~i~) (n[m]{.smallcaps})                                                     
  --- ----------------------- ------- ------------------------------------ ------ ------ -------- ------ ------ ------ ----- ------------
      AVP                     323     0.29                                 0.68   0.45   1.2      2.6    1.1    1.7    1.7   74, 84
      dAVP                    1745    0.20                                 0.37   0.76   5        10.8   3.8    0.97   --    74, 84
  1   d\[Cha^4^\]AVP          133.6   1.40                                 1.2    12.7   750      2297   151    1430   240   69, 72, 74
  2   d\[Cha^4^, Lys^8^\]VP   0.82    1.9                                  2.2    596    11 484   9093   283    586    141   85, 86
  3   d\[Leu^4^\]AVP          378     0.04                                 0.23   3.1    245      1252   44.1   481    211   72, 74
  4   d\[Leu^4^, Lys^8^\]VP   10.5    0.16                                 0.51   101    6713     3786   69.3   64     29    74, 86, 87

V~1b~ receptor agonists ([Table 5](#tbl5){ref-type="table"})
============================================================

AVP was synthesised in 1954 ([@b3]) ([Table 5](#tbl5){ref-type="table"}).The first 'selective' V~1a~ agonist \[Phe^2^\]OVT was synthesised 10 years later in 1964 ([@b81]). The first selective V~2~ agonist dDAVP was reported in 1967 ([@b80]). Yet, it was not until 2002, almost 50 years after the synthesis of AVP, that the first selective agonist for the human V~1b~ receptor, d\[Cha^4^\]AVP was synthesised ([@b69]). The reasons why this discovery took so long have been documented by Manning *et al.* ([@b1]).

[Table 5](#tbl5){ref-type="table"} lists four analogues of dAVP (peptides **1**--**4**) that exhibit high affinities for both the rat and human V~1b~ receptors. d\[Cha^4^\]AVP (peptide **1**) was the first V~1b~ agonist that was shown to be selective for the human V~1b~ receptor ([@b69]). d\[Leu^4^\]AVP (peptide **3**) has later been shown to be a selective agonist for the human V~1b~ receptor ([@b72]). Both (peptides **1** and **3**) exhibit high affinities for the rat V~1b~ receptor. However, they also possess high *in vivo* antidiuretic activity. Thus, neither is a selective V~1b~ agonist in the rat.

Replacement of the Arg^8^ residue in (peptides **1** and **3**) by a Lys^8^ residue to give d\[Cha^4^,Lys^8^\]VP (peptide **2**) and d\[Leu^4^,Lys^8^\]VP (peptide **4**), respectively, resulted in the first peptides that are selective V~1b~ agonists in the rat ([@b73], [@b74]). It was subsequently shown that both peptides **1** and **2** are also highly selective for human V~1b~ receptors ([@b86]). It bears noting that d\[Leu^4^,Lys^8^\]VP had been reported to be a weak antidiuretic V~2~ agonist/weak vasopressor agonist in the rat ([@b87]), 30 years before the V~1b~ receptor was first predicted and/or cloned ([@b88]). The selective V~1b~ agonists d\[Cha^4^\]AVP and d\[Leu^4^,Lys^8^\]VP have been used as a research tool in a number of studies ([@b1], [@b20], [@b62], [@b73], [@b89], [@b90]). Furthermore, d\[Leu^4^,Lys^8^\]VP has been utilised in the design of a series of fluorescent ligands for the V~1b~ receptor ([@b47]).

Selective V~1a~ antagonists ([Table 6](#tbl6){ref-type="table"})
================================================================

###### 

Design of Highly Selective V~1a~ Antagonists.

                                                        Anti-OT (*in vitro*)   Anti-OT (*in vivo*)   Anti-V~1a~ (*in vivo*)              
  --- ------------------------------------------------- ---------------------- --------------------- ------------------------ ---------- ----
  1   d(CH~2~)~5~\[Tyr(Me)^2^\]AVP (Manning compound)   8.13                   6.62                  8.62                     100        91
  2   d(CH~2~)~5~\[Tyr(Me)^2^, Dap^5^\]AVP              5.83                   ND^c^                 7.49                     Infinite   92
  3   d(CH~2~)~5~\[Tyr(Me)^2^, Dab^5^\]AVP              ND^c^                  ND^c^                 6.71                     Infinite   92

OT, oxytocin; d(CH)~5~ = β-mercapto-β,β-cyclopentamethylenepropionyl. ^a^*In vitro* pA~2~ values represent the negative logarithm to the base 10 of the average molar concentration \[[m]{.smallcaps}\] of the antagonist that reduces the response to 2 × units of agonist to the equal the response seen with 1 × units of agonist administered in the absence of the antagonist. ^b^*In vivo* pA~2~ values are estimated because the molar concentration for the in vivo pA~2~ is estimated by dividing the effective dose (ED) by the estimated volume of distribution of (67 ml/kg) ([@b52]). ED is defined as the dose (nmol/kg intravenously) of the antagonist that reduces the response to 2 × units of agonist to the response with 1 × units of agonist administered in the absence of the antagonist. ^c^ND, not detectable (weak agonist, \< 0.03 U/mg).

d(CH~2~)~5~\[Tyr(Me)^2^\]AVP, also known as Manning compound (peptide **1**; [Table 6](#tbl6){ref-type="table"}) is a potent VP V~1a~ antagonist/weak VP V~2~ agonist ([@b91]). It is thus highly selective for V~1a~ receptors versus V~2~ receptors. It is, however, a potent *in vitro* OT antagonist and a fairly potent OT antagonist *in vivo* ([@b91]). It has found widespread use as a selective V~1a~ antagonist in a variety of studies on the peripheral and central effects of AVP. Indeed, it has become the most widely used V~1a~ antagonist reported to date. Isosteric modifications of d(CH~2~)~5~\[Tyr(Me)^2^\]AVP at position 5 with diaminopropionic acid (Dap) and diaminobutyric acid (Dab) led to d(CH~2~)~5~\[Tyr(Me)^2^,D~ap~^5^\]AVP (peptide **2**; [Table 6](#tbl6){ref-type="table"}) and d(CH~2~)~5~\[Tyr(Me)^2^,Dab^5^\]AVP (peptide **3**; [Table 6](#tbl6){ref-type="table"}), respectively. Both peptides are devoid of anti OT activity *in vivo* ([@b92]). Although both peptides are much less potent than d(CH~2~)~5~\[Tyr(Me)^2^\]AVP as V~1a~ antagonists, because they lack anti OT potency *in vivo,* they are highly selective for V~1a~ receptors in the rat. Their use is recommended for *in vivo* studies that require discrimination between V~1a~ and OT receptors in the rat.

Nonselective and selective cyclic and linear V~2~/V~1a~ antagonists for rat receptors
=====================================================================================

It was not until 1981, almost 30 years after the first laboratory synthesis of OT, that the first cyclic AVP V~2~/V~1a~ antagonists were reported ([@b8]) ([Table 7](#tbl7){ref-type="table"}). Six years later, the unexpected discovery of the first linear V~2~/V~1a~ antagonists was reported ([@b93]). The early cyclic and linear V~2~/V~1a~ antagonists were nonselective for V~2~ receptors. Further modifications of the early cyclic V~2~/V~1a~ antagonists led to the discovery of selective cyclic V~2~ antagonists ([@b94]). Some of the most commonly used nonselective cyclic and linear V~2~/V~1~ antagonists (peptides **1**, **2**, **7**) and selective cyclic V~2~ antagonists (peptides **3**--**6**) are given in [Table 7](#tbl7){ref-type="table"}. Peptide **6** ([@b101]) has been very useful for the design of a lanthanide cryplate-labelled ligand as a fluorescent probe for measuring receptor dimerisation ([@b48]) Peptide **8** (HO-LVA) ([@b95]), a potent linear V~1a~ antagonist, has served as a precursor for the radioiodinated V~1a~ ligand \[^125^I\]HO-LVA ([@b97]). This radioligand has found widespread use as a selective probe for V~1a~ receptors. Its affinities for rat receptors are given in [Table 12](#tbl12){ref-type="table"}. A number of these V~2~/V~1a~ antagonists (peptides **1**--**3**; [Table 7](#tbl7){ref-type="table"}) exhibit oxytocic antagonism *in vivo*. The remaining peptides **4**--**8** have not been evaluated in anti-OT assays. Caution should be exercised in using any of the peptides in [Table 7](#tbl7){ref-type="table"} as selective V~2~ ligands. The affinities of peptides **1** and **5** for the human and rat V~2~ receptors are given in [Table 12](#tbl12){ref-type="table"}.

###### 

Nonselective and Selective Cyclic and Linear V~2~/V~1a~ Antagonists for Rat Receptors.

                                                                  Antiantidiuretic (A) (anti-V~2~)   Antivasopressor (P) (anti-V~1a~)   Antioxytocic *In vivo*                            
  --- ----------------------------------------------------------- ---------------------------------- ---------------------------------- ------------------------ ------ ---------- ------ ------------
  1   d(CH~2~)~5~\[D-Tyr(Et)^2^\]VAVP                             1.1                                7.81                                                        8.22   7.47^\*^   0.4    98
  2   desGly,d(CH~2~)~5~\[D-Tyr(Et)^2^, Val^4^\]AVP               1.5                                7.69                               0.45                     8.17   6.98^\*^   0.3    99
  3   d(CH~2~)~5~\[D-Ile^2^, Ile^4^\]AVP                          0.67                               8.04                               0.45                     6.42   6.90^\*^   39     94
  4   desGly-NH~2~,d(CH~2~)~5~\[D-Ile^2^, Ile^4^\]AVP             0.90                               7.88                               26                       ∼5.2              ∼440   100
  5   d(CH~2~)~5~\[D-Ile^2^, Ile^4^, Ala-NH~2~^9^ \]AVP           0.46                               8.16                               ∼400                     6.25              83     100
  6   d(CH~2~)~5~\[D-Tyr(Et)^2^, Ile^4^, Eda^9^\]AVP              0.77                               8.00                               38                       8.33                     101
  7   Aaa-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH~2~             0.53                               8.11                               0.32                     7.75              2.3    48, 95
  8   4-HO-Phaa-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-NH~2~(HO-LVA)   Agonist                            0.056 U/mg                         1.2                      8.47                     12, 96, 97

Aaa, adamantaneacetyl; Eda, ethylenediamine; 4-HO-Phaa, 4-hydroxyphenylacetyl. ^\*^*In vivo* anti-oxytocin (OT) potencies were reported previously ([@b10]), ^a^The effective dose (ED) is defined as the dose (in nmol/kg) that reduces the response to 2 × units of agonist to equal the response to 1 × unit. ^b^ Estimated *in vivo* pA~2~ values represent the negative logarithms of the EDs divided by the estimated volume of distribution (67ml/kg) ([@b52]).

Some nonselective and selective oxytocin antagonists ([Table 8](#tbl8){ref-type="table"})
=========================================================================================

###### 

Some Nonselective and Selective Oxytocin Antagonists in the Rat.

                                                            Antioxytocic (anti-OT)                                                                                          
  --- ----------------------------------------------------- ------------------------ ------------ ------ ------------------------ ------ --------------------------- ------ ----------
  1   d\[D-Tyr(Et)^2^,Thr^4^\]OVT (atosiban)                8.29                     Antagonist          Agonist 0.02 (IU/μmol)          Agonist 0.04 (IU/μmol)             106
                                                            7.71                     5.95         7.05   48.5                     6.14   Antagonist (pA~2~ ≍ 5.9)    8      104
  2   d(CH~2~)~5~\[Tyr(Me)^2^\]OVT                          8.52                     4.2          7.37   0.80                     7.96   ≍ 0.01                      0.2    103
  3   desGly-NH~2~,d(CH~2~)~5~\[Tyr(Me)^2^, Thr^4^\]OVT     7.89                     1.3          7.69   23                       6.48   Antagonist (pA~2~ ≍ 5.5)    17.7   104
  4   d(CH~2~)~5~\[Tyr(Me)^2^, Thr^4^, Tyr-NH~2~^9^ \]OVT   7.63                     1.0          7.83   6.6                      7.02   ≍ 0.015                     6.6    104, 105
  5   desGly-NH~2~,d(CH~2~)~5~\[D-Tyr^2^, Thr^4^\]OVT       7.77                     2.85         7.37   272                      5.39   Antagonist (pA~2~ \< 5.5)   95     104

*In vitro* pA~2~ values represents the negative logarithm to the base 10 of the average molar concentration \[[m]{.smallcaps}\] of antagonist which reduces the response to 2 × units of agonist to the response with × units of agonist. ^b^The effective dose (ED) is defined as the dose (in n[m]{.smallcaps}/kg) of antagonist that reduces the response to 2 × units of agonist to the response with × units of agonist administered in the absence of antagonist. ^c^Estimated *in vivo* pA~2~ values represent the negative logarithms of the 'effective dose' divided by the estimated volume of distribution (67 ml/kg) ([@b52]). ^d^ED ratio = anti-vasopressor ED/antioxytocic ED.

The OT antagonists listed in [Table 8](#tbl8){ref-type="table"} have all found widespread use as pharmacological tools. Under the tradename Tractocile, atosiban (peptide **1**) has been approved for clinical use in Europe for the prevention of premature labour ([@b102]). All of these OT antagonists exhibit varying degrees of anti-V~1a~ potency in the rat. Thus, they are far from being selective. Indeed, d(CH~2~)~5~\[Tyr(Me)^2^\]OVT, one of our original OT antagonists ([@b103]), is five-fold more potent as a vasopressor antagonist than as an OT antagonist ([@b103]). Peptide **5**, desGly-NH~2~, d(CH~2~)~5~ \[D-Tyr^2^,Thr^4^\]OVT ([@b104]) is the most selective OT antagonist in [Table 8](#tbl8){ref-type="table"}. It has been used in a variety of studies. These are listed under 'Research Uses'.

This OT receptor antagonist also exhibits a high affinity and selectivity for the human OT receptor ([Table 12](#tbl12){ref-type="table"}). Peptide **3**, desGly-NH~2~,d(CH~2~)~5~\[Tyr(Me)^2^Thr^4^\]OVT, although much less selective than OTA No. 5, has proved to be very useful as a research tool in the Neumann laboratory for a wide variety of studies on the central effects of OT. Some examples of these studies are listed under 'Research Uses'.The ^125^I derivative of peptide 4, d(CH~2~)~5~\[Tyr(Me)^2^,Thr^4^,Tyr-NH~2~^9^\]OVT ([@b105]) has found widespread use as a probe of OT receptors.

Nonpeptide vasopressin antagonists as pharmacological tools and therapeutic agents ([Table 9](#tbl9){ref-type="table"})
=======================================================================================================================

###### 

Nonpeptide Vasopressin Antagonists as Pharmacological Tools and Therapeutic Agents.

  Number   Receptor Type   Company    Code          Name          Supplier                                     Status                                                            Reference: synthesis   Reference: pharmacological use   Reference: clinical use
  -------- --------------- ---------- ------------- ------------- -------------------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------- -------------------------
  1        V~1a~           Sanofi     SR49059       Relcovaptan   Tocris                                       Phase II (terminated)                                             45, 116                117                               
  2        V~1a~           Pfizer     PF-00738245   No name       Pfizer                                       New compound                                                      118                                                      
  3        V~1a~           Otsuka     OPC-21268     No name       Tocris Sigma-Aldrich                         Phase II Japan stopped US/Europe                                  107                                                      
  4        V~1b~           Sanofi     SSR149415     Nelivaptan    Axon Medchem                                 Preclinical (terminated)                                          45, 119, 164           120, 147, 148, 150                
  5        V~2~            Otsuka     OPC-41061     Tolvaptan     Shanghai DND Pharm-Technology Co.,Inc.       Approved by US Food and Drug Administration oral use (Samsca)     108                    115                              111--115, 121--123
  6        V~2~            Sanofi     SR121463(B)   Satavaptan    None                                         Phase III (terminated)                                            45                     124--126                          
  7        V~2~            Otsuka     OPC-31260     Mozavaptan    Otsuka; Anhui Pharmaceutical Co., LTD        Phase II                                                          127                                                      
  8        V~2~/V~1a~      Astellas   YM-087        Conivaptan    LGM Pharma, Beijing HuameiHuli Biochem Ltd   Approved by US Food and Drug Administration i.v. use (Vaprisol)   127                    152                              111, 112, 128, 129

The search for nonpeptide antagonists for the AVP, V~1a~, V~1b~ and V~2~ receptors has been pursued with vigour by many pharmaceutical companies, most notably Otsuka, Sanofi, Azevan, Astellas, Wyeth-Ayerst, Johnson & Johnson, Yamanouchi and Pfizer ([Table 9](#tbl9){ref-type="table"}). In 1991, Otsuka reported the first nonpeptide V~1a~ antagonist OPC-21268 (No. **3**; [Table 9](#tbl9){ref-type="table"}) ([@b107]). During the subsequent 20 years, a number of promising nonpeptide V~1~, V~1b~, and V~2~ antagonists have been reported ([@b1], [@b45]). [Table 9](#tbl9){ref-type="table"} lists a number of these, together with references to: (i) their original synthesis ([@b45], [@b107], [@b108], [@b110], [@b116]--[@b119], [@b127], [@b164]); (ii) some research uses ([@b115], [@b117], [@b120], [@b124], [@b126], [@b147], [@b148], [@b150], [@b152]); and (iii) their clinical uses ([@b109; @b111; @b112; @b113; @b114; @b115; @b121; @b122; @b123; @b128; @b129]). Most notable, are the Otsuka V~2~ antagonist (Tolvaptan, No. **5**; [Table 9](#tbl9){ref-type="table"}) first reported in 1998 by Yamamura *et al.*, ([@b108]) and shown to be effective in the treatment of hyponatraemia ([@b109]) and the Astellas V~2~/V~1a~ antagonist (Conivaptan, No. **8**; [Table 9](#tbl9){ref-type="table"}) first reported in 1997 by Tahara *et al.* ([@b110]). Both conivaptan and tolvaptan have been approved for clinical use by the Food and Drug Administration ([@b111; @b112; @b113; @b114; @b115]). The development of nonpeptide V~1a~, V~1b~ and V~2~ antagonists at other companies has recently been abandoned as a resut of failures in clinic trials. Thus, Sanofi, which had reported the V~1a~ antagonist SR-49059, Relcovaptan (No. **1**; [Table 9](#tbl9){ref-type="table"}), the V~1b~ antagonist SSR-149415, Nelivaptan (No. **4**; [Table 9](#tbl9){ref-type="table"}) and the V~2~ antagonist SR-121463 (B) Satavaptan (No. **6**; [Table 9](#tbl9){ref-type="table"}), all highly promising candidates for therapeutic development ([@b45]), has recently abandoned its entire AVP nonpeptide antagonist programme. It should be noted that these three Sanofi nonpeptide antagonists are highly useful pharmacological tools. The commercial availability of some of these nonpeptide VP antagonists is shown in [Table 9](#tbl9){ref-type="table"}. Human and rat receptor affinities for all three Sanofi V~1a~, V~1b~ and V~2~ nonpeptides are given in [Table 12](#tbl12){ref-type="table"}.

Nonpeptide oxytocin antagonists and a nonpeptide oxytocin agonist ([Table 10](#tbl10){ref-type="table"})
========================================================================================================

###### 

Non peptide Oxytocin Antagonists and a Nonpeptide Agonist.

  Compound        Number   Code (name)               Company                     Supplier                                 Status                  Reference: original synthesis, structure and pharmacologocal properties)   Reference: use
  --------------- -------- ------------------------- --------------------------- ---------------------------------------- ----------------------- -------------------------------------------------------------------------- ----------------
  OT antagonist   1        L-368,899                 Merck                       Tocris                                   Phase II Discontinued   46, 130                                                                    134--136
                  2        L-371,257                 Merck                       Tocris                                   Phase II Discontinued   46                                                                         141
                  3        WAY-162720                Wyeth-Ayerst (now Pfizer)   No                                       Failed in preclinical   131                                                                        141
                  4        GSK2211149A (Retosiban)   Glaxo SmithKline            Simagchem; Manus Aktteva Biopharma LLP   Phase II completed      132, 133                                                                    
  OT agonist      1        WAY-267464                Wyeth-Ayerst (now Pfizer)   Tocris                                   Failed in preclinical   138, 140                                                                   137, 141

A number of companies have been active in this area. In the mid-1990s, Merck reported a number of promising nonpeptide OT antagonists ([@b46], [@b130]) ([Table 10](#tbl10){ref-type="table"}). Most notable were L-368,899 (No. **1**; [Table 10](#tbl10){ref-type="table"}) and L-371, 257 (No. **2**; [Table 10](#tbl10){ref-type="table"}). Both of these failed in clinical development for the treatment of premature labour. Merck subsequently abandoned its nonpeptide OT antagonist programme. Similarly, Wyeth-Ayerst (now Pfizer) reported that its nonpeptide OT antagonist WAY-1627720 ([@b131]) (No. **3**; [Table 10](#tbl10){ref-type="table"}) failed in preclinical development. Glaxo SmithKline is now the only company pursuing the clinical development of a nonpeptide OT antagonist. Its promising nonpeptide OT antagonist GSK 2211149A (Retosiban) ([@b132], [@b133]) is currently in a Phase II clinical trial. Its human and rat OT receptor affinities are given in [Table 12](#tbl12){ref-type="table"}. Its OT selectivities for human OT/VP receptors are excellent. Although the Merck and Wyeth-Ayerst nonpeptide OT antagonists have failed in clinical development, they are proving to be very useful as research tools ([@b134; @b135; @b136; @b137; @b138]) The Merck compounds are now available from TOCRIS. The nonpeptide OT agonist WAY-267464 reported by Pfizer ([@b131]) appeared to have promise as a therapeutic agent for the treatment of anxiety disorders such as autism spectrum disorders ([@b139]). However, its failure in preclinical development led to the abandonment of the nonpeptide OT agonist programme at Pfizer ([@b44]). WAY 267464 is now available from TOCRIS. Presently, there are no other companies pursuing the development of nonpeptide OT agonists.

The use of radiolabelled molecules, agonists and antagonists for characterising receptor affinities for OT and VP ([Tables 11](#tbl11){ref-type="table"} and [12](#tbl12){ref-type="table"})
============================================================================================================================================================================================

###### 

Common Agonists to Oxytocin (OT)/Arginine Vasopressin (AVP) Receptors^a^.

  --
  --

###### 

Common Antagonists to Oxytocin (OT)/Arginine Vasopressin (AVP) Receptors^a^.

  --
  --

Some history
------------

Initially in the 1960, the affinity, selectivity and potency of analogues for the different VP/OT receptors were deduced by *in vivo* bioassays such as oxytocic, antidiuretic and pressor tests (see above), which reflected their activity through the OT receptor, V~2~ and V~1a~ receptors, respectively. The characterisations performed at that time did not take into account the V~1b~ receptor, which was discovered only in the 1980s ([@b142]). As noted above, this led to a long delay in the discovery of selective ligands for the V~1b~ receptor. Nevertheless, the use of bioassays allowed the identification of key structure/function relationships of a large number of analogues and still represents a milestone in our understanding of OT/AVP selectivity ([@b1; @b7; @b8; @b9; @b10; @b11; @b12; @b13; @b14; @b15; @b16; @b17; @b18]). Furthermore, because the data obtained using these *in vivo* tests integrated several ADME (Absorption, Distribution, Metabolism and Elimination) parameters, the values obtained reflect the *in vivo* physiological activity of the peptide being studied. These values sometimes differed from those obtained by *in vitro* pharmacological tests.

In the 1970s, the development of radiolabelled VP/OT analogues ([@b143]) and the discovery of second messenger cascades such as cAMP ([@b67]), calcium and inositol phosphate ([@b144]) made possible the determination of more reliable pharmacological parameters reflecting more precisely the interaction between analogues and their specific receptors. Binding assays with radiolabelled ligands conducted on plasma membrane preparations allowed the determination of the affinity (K~d~) of a given molecule for a given VP/OT receptor subtype, a parameter which intrinsiquely characterises the analogue/receptor association ([@b145]). Second messenger measurements allowed the characterisation of its functional activity in order to measure precise functional effects. Comparison of the affinities of one analogue for the all receptors of the VP/OT family allowed the determination of its selectivity towards a given receptor isoform. Moreover, the ability of a given analogue to activate, inhibit or leave unaffected second messenger production in cell cultures, provided important insights into its pharmacological status (agonist, partial agonist, pure antagonist, inverse agonist). Such classical pharmacological assays have efficiently served the scientific community for the last three decades and allowed the characterisation of the numerous VP/OT analogues designed and synthesised during this period ([@b1]).

Conundrums posed by pharmacological data
========================================

From all the *in vitro* and *in vivo* pharmacological studies carried out on OT and VP agonists and antagonists, three intriguing features have emerged; namely: (i) lack of receptor selectivity; (ii) species differences; and (iii) *in vitro in vivo* difference. In [Tables 11](#tbl11){ref-type="table"} and [12](#tbl12){ref-type="table"}, we have listed the most commonly used agonists and antagonists available for each VP/OT receptor isoform in three mammalian species: human, rat and mouse.

The affinities (K~i~) of these isoforms have been measured using classical pharmacological tests and their agonist or antagonists properties determined using classical second messenger assays. As proposed in previous reviews ([@b156], [@b157]), receptor subtype selectivity can be defined, within a single species, on the basis of the ability of a compound to bind to a single VP/OT receptor isoform with a nanomolar affinity, at the same time displaying, for the three other receptor isoforms, an affinity at least two orders of magnitude lower. The compounds that fullfill these requirements are highlighted with light grey in [Tables 11](#tbl11){ref-type="table"} and [12](#tbl12){ref-type="table"}. It immediately appears from this criterion that only a very few analogues are selective. A major problem is also that selectivity is not conserved among species as a result of subtle but nevertheless crucial differences in receptor pharmacology. Despite these limitations, the use of selective compounds still represents the best experimental strategy to unambiguously characterise VP/OT receptors in a given biological sample, keeping in mind that receptor selectivity for any given compound is: (i) strictly dependent upon the receptor species considered; (ii) usually lost if high doses (100-fold the K~i~) of a selective compound are used; and (iii) dependent upon the biological models tested. Experiments performed on membrane preparations or on cell cultures generally need lower concentrations of selective analogue compared to experiments performed on organ slices, where drugs need to diffuse within the tissues and may be rapidly degraded.

It should also be noted that the pharmacological profile of any given compound determined by classical tests on membranes or cell models cannot be directly translated *in vivo* without adequate controls. Adsorption, distribution in different biological compartments, and metabolism greatly interfere with the biological activity of drugs, sometimes completely altering their pharmacological properties.

For example, \[Phe^2^Orn^8^\]VT (also known as \[Phe^2^\]OVT), which does not display any V~1a~ selectivity in classical binding experiments ([Table 11](#tbl11){ref-type="table"}), has been characterised as a selective V~1a~ agonist *in vivo* in rats ([Table 4](#tbl4){ref-type="table"}) ([@b81]).

Concerning selective agonists, it should also be noted that a major difference exists between the two natural hormones, OT and VP. Although OT is selective for the human OT receptor, VP is not, because it binds with similar affinities to V~1a~, V~1b~ V~2~ and OT receptors. This may explain why VP may trigger physiological functions *in vivo* via OT receptors, as described previously ([@b158]). However, fully characterised selective agonists for human V~1a~ receptor (F 180, FE202158), human V~1b~ receptor (d\[Cha^4^\]AVP); rat V~1b~ receptor (d\[Leu^4^,Lys^8^\]AVP), rat OT receptor \[Thr^4^,Gly^7^\]OT and rat V~2~ receptor (dDAVP) are now available ([Table 11](#tbl11){ref-type="table"}). For the rat, V~2~ receptor d\[Thi^3^\]VDAVP ([@b15], [@b159]) appears to be the best selective agonist as a result of its good V~2~ versus V~1b~ selectivity.

Among the several antagonists reported and currently employed, only a few have been fully characterised and have been demonstrated to be selective whithin a species ([Table 12](#tbl12){ref-type="table"}).

Among the OT receptor antagonists, SSR126768A has been shown to be a very selective antagonist for both human and rat OTR and GSK 221149A for human OT receptor. Manning compound is relatively selective for the rat V~1a~ receptor (but not for the human V~1a~ receptor) for which SSR49059 should be preferred. Finally, SSR149415 ([@b147]) is selective for both the human and the rat V~1b~ receptor isoforms, whereas SSR121463(A) is highly selective for the human V~2~ receptor. Concerning the SSR149415 and SSR49059, it should be noted that different laboratories have obtained different values for their affinities, probably depending on the binding assay employed (i.e. competition against a radioactive agonist or antagonist) ([@b89]). In our opinion, the values obtained in competition experiments using radiolabelled agonists will better correlate with biological antagonistic activity *in vitro* and *in vivo* and should be preferred.

Until now, other analogues commonly employed as 'selective' have not been fully characterised and, when they are used at high doses, could lead to ambiguous results in species in which their pharmacological properties have not been assessed. It should be noted that the pharmacology of OT/VP analogues on mouse receptors is still very limited, representing a gap that needs to be filled; in particular, for the relevance that genetically-modified mouse models have acquired in translational medicine.

The lack of selective analogues for some rat, mouse and human receptor isoforms makes the design and synthesis of new molecules very necessary. The restriction of radioactivity approaches in laboratory practice and the need to easily test a large number of molecules led to the development of new assays using the gene reporters. Such tests using the measurement of reporter gene activities allows an easy screening of a large number of molecules and rapid identification of 'lead molecules' ([@b83]).

Yet, these '*in vitro* methodologies' also have some limitations. First, they can be used only in transfected cells and not in native models. Moreover, according to the second messenger cascade associated with the receptor being considered (cAMP for the V~2~, InsP3 for the V~1a~, V~1b~ and OT receptor isoforms), such assays require the use of different reporter genes. This may introduce a bias in the determination of receptor selectively. It is also well known that assays using luciferase gene expression and luciferase activity measurements involve a strong amplification of the initial receptor-mediated second messenger accumulation. This prevents the good determination of the agonist or partial agonist properties of the analogue tested. One needs to be aware of the limitations of these recent '*in vitro* methodologies' and to verify, using classical pharmacological tests, the selectivity, affinity and functional potencies of the lead compounds characterised by this approach. Obviously, to move to clinical development, the best approach would be to test the compounds of interest by *in vivo* technologies similar to those used to evaluate virtually all of the peptides in [Tables 1](#tbl1){ref-type="table"}, [3](#tbl3){ref-type="table"}--[8](#tbl8){ref-type="table"}.

New technologies for screening more selective VP/OT analogues
=============================================================

Recently, new physical techniques involving label-free biosensors have been proposed for pharmacological screening of muscarinic and corticotrophic analogues ([@b165]). These methods are based on the measurement of cell shape changes induced by ligand-receptor interactions. Such techniques have the advantage of being performed on native cells and do not require the use of radioactive molecules. Their efficiency for testing new VP/OT molecules may represent another alternative for screening new analogues.

Finally, a new bioluminescence or fluorescence resonance energy transfer (BRET or FRET) approach in which analogues could be screened for their capability to promote receptor coupling and activation of single G-protein isoforms has been recently applied to the human OT receptor ([@b166]). This technique allows the precise characterisation of which G protein is associated with which receptor isoform. Thus, for example, d(CH~2~)~5~\[D-2-Nal^2^,Thr^4^,Tyr-NH~2~^9^\]OVT (OTA) and atosiban ([@b160]) ([Table 12](#tbl12){ref-type="table"}) were found to be entirely biased respectively toward Gi1 or Gi3 activation ([@b166]). However, this technique cannot be used on native tissues or primary cultures.

The recent development of fluorescent ligands for a better knowledge of central and peripheral VP/OT receptors
==============================================================================================================

Design and use of classical fluorophores
----------------------------------------

Receptors of the AVP and OT family are important in the regulation of the stress processes ([@b167]). Centrally, the V~1a~, V~1b~ and OT receptors have been involved in stress and especially in learning and memory processes. Important data have been obtained by the use of knockout animals but, after a period of cloning and pharmacological characterisation in the last decade, it became necessary to elucidate the distribution of these receptors to better understand their central functions *in vivo*.

Although several publications describe the AVP V~1a~, V~2~ and OT receptor distribution by using autoradiography ([@b105], [@b168], [@b169]) or immunodetection ([@b170]), the lack of selective V~1b~ radio-labelled VP analogues or of receptor antibodies has hindered progress in the detection of receptor distribution in native tissues. Results obtained by molecular approaches such as reverse transcriptase-polymerase chain reaction ([@b62], [@b88]) or mRNA detection by *in situ* hybridisation ([@b171; @b172; @b173]), although more accurate, did not provide clear information regarding the brain regions detected by immunostaining. Thus, developing fluorescent ligands to decipher AVP receptor distribution in the brain and at the periphery, and to study molecular interactions such as receptor dimerisation, appeared as an absolute necessity.

Various fluorescent analogues of AVP and OT have been synthesised for several receptors of the VP/OT family ([@b174]). Thus, good fluorescent V~1a~ and OT ligands have been produced, although no good fluorescent specific ligand was available to selectively detect central and peripheral V~1b~ receptors.

In our previous work ([@b69; @b73; @b74]), by replacing the glutamine^4^ of the natural AVP with a cyclohexylalanine or a leucine, the arginine^8^ by a lysine and by removing the NH~2~ of the cysteine^1^ to increase stability towards aminopeptidases, we produced analogues showing an increased selectivity for the V~1b~ receptors ([Table 5](#tbl5){ref-type="table"}). d\[Leu^4^,Lys^8^\]VP (Peptide **4**; [Table 5](#tbl5){ref-type="table"}) was found to be selective for the rat V~1b~ receptors and, to a lesser extent, for the human hV~1b~ receptors, conserving a nanomolar affinity for these receptor isoforms ([@b73; @b74]). We have taken advantage of the Lys^8^ residue in d\[Leu^4^,Lys^8^\]VP with its epsilon NH~2~ group to introduce fluorophores on its side chain. This allowed us to create fluorescent tools that would conserve the pharmacology of the d\[Leu^4^,Lys^8^\]VP, to resist degradation and to selectively decorate the plasma membrane of Chinese hamster ovary cells expressing V~1b~ and/or OT receptors with an excellent resolution ([@b47]).

Different fluorophores were attached to the d\[Leu^4^,Lys^8^\]VP: First, the antraniloyl group (Atn), a small fluorescent molecule of 97 Da highly sensitive to microenvironmental changes ([@b175]) may also be a good donor in FRET experiments to identify V~1b~ receptor homodimers *in vivo*. We have also selected the Alexas (Molecular Probes) for their brightness and their resistance to photobleaching ([@b176]). We have used Alexa 488 and Alexa 647, with the latter being one of the brightest fluorescent molecules reported so far ([@b177]).

The pharmacological properties (binding, coupling to phospholipase C) of fluorescent analogues of d\[Leu^4^,Lys^8^\]VP indicate that they conserved a very good selectivity for V~1b~ versus V~1a~ and V~2~ receptors, and remained full agonists. These properties allow receptor labelling and measurement of biological activity at the cellular level. Thus, these new fluorescent analogues are promising tools for the detection of functional V~1b~ or OT receptors in human ([@b47]) and in rat native tissues.

Use of long life fluorophores
-----------------------------

However, it should be noted that, except for very recent ones, all the ligands previously reported were designed with classical fluorophores, exhibiting short-lived fluorescence properties (fluorescence half-time life in the 10 ns range). Most of them were essentially used to follow internalisation in cell lines ([@b146; @b178]) or to label receptors in a native context ([@b179]). Interestingly, a first nonpeptide antagonist with a nanomolar affinity for the human V~2~ receptor has been developed ([@b180]). This ligand will find application in fluorescence polarisation-based binding assays aiming to screen for small organic molecule libraries.

Recently, fluorescence-based strategies have been extensively used to study molecular interactions. Thus, the FRET approach was used to demonstrate G protein-coupled receptors oligomerisation ([@b181; @b182]). Regarding AVP and OT receptors, various experimental approaches based on chimeric receptor expression in cell lines have been developed to analyse receptor oligomers. The studies have used receptors fused either to small tags recognised by fluorescent antibodies ([@b183; @b184]), or to bioluminescent or fluorescent proteins ([@b185; @b186]), or to suicide enzymes ([@b48]). However, these strategies were not relevant for proving the existence of such receptor complexes in native tissues. Therefore, a FRET strategy based on the indirect labelling of receptors with fluorescent donor and acceptor ligands has been recently developed ([@b48]). Unfortunately, because of the overlap between excitation and emission spectra of the donor and acceptor fluorophores on one hand, and of the high autofluorescence of the biological preparation on the other hand, specific FRET could hardly be detected. To improve the signal-to-noise ratio, lanthanide cryptate-labelled ligands were designed and characterised. Despite the size of the cage, these ligands still display very good affinities for the V~1a~ and OT receptors ([@b48]). Lanthanide cryptates display interesting fluorescent properties because they have a fluorescent half-time life of approximately 1 ms (i.e. 100 000-fold greater than classical fluorophores), allowing time-resolved FRET experiments to be set up ([@b187]). Experiments using these new probes have been performed not only on AVP V~1a~ and V~2~ receptors and on OT receptors expressed in cell lines, but also on OT receptors naturally expressed in lactating rat mammary gland. The sensitivity is such that it has been possible to prove the existence of OT receptor dimers in this latter native tissue ([@b48]).

These newly-synthesised ligands and those that exhibit high quantum yield have also been used to develop original binding assays. These assays, based on time-resolved FRET between compatible fluorophores carried by tagged receptors and ligands, display very good sensitivities and are safer than radioactive-based assays ([@b188; @b189; @b190]).

Therapeutics uses of peptide and nonpeptide oxytocin and vasopressin agonists and antagonists ([Table 13](#tbl13){ref-type="table"})
====================================================================================================================================

###### 

Food and Drug Administration Approved Peptide and Nonpeptide Drugs from the Oxytocin (OT)/Arginine Vasopressin (AVP) Field.

  OT/AVP field                                      
  ------------------------------------------------- -------------------------------------
  Peptides[a](#tf13-1){ref-type="table-fn"}         Nonpeptides^b^
  Carbetocin (Duratocin, Depotocin, Sofla, Pabal)   Conivaptan hydrochloride (Vaprisol)
  Desmopressin (Minirin, DDAVP)                     Tolvaptan
  Ornithine vasopressin (Ornipressin, POR-8)        
  Lypressin (Diapid, LVP)                           
  Oxytocin                                          
  Terlipressin (glypressin)                         
  Vasopressin (Pitressin)                           
  Atosiban (in Europe)                              

See Reichert (194). ^b^See Ferguson-Myrthil (115).

[Table 13](#tbl13){ref-type="table"} lists the seven peptides and two nonpeptide drugs in the OT and AVP field that have been approved for therapeutic use. Numerous recent studies point to the use of OT as a potential new therapy for the treatment of a broad range of psychiatric disorders ([@b24; @b33; @b34]). Also, a very recent report suggests the exciting prospect that OT may have potential for the treatment of human obesity and type 2 diabetes ([@b191]).

To date, only two nonpeptides, the VP V~2~/V~1a~ antagonist conivaptan and the VP V~2~ antagonist tolvaptan have been approved for clinical use ([@b112; @b113; @b114; @b115; @b123; @b192]). The nonpeptide OT antagonist retosiban ([@b132; @b133]) is currently in a Phase II clinical trial. Clinical trials with other nonpeptide VP, V~1a~ and V~1b~ antagonists shown in [Table 9](#tbl9){ref-type="table"} and with the other OT antagonists and the OT agonist shown in [Table 10](#tbl10){ref-type="table"} have been terminated ([@b44]). No new nonpeptides in this field are currently in clinical trial. Thus, the early promise of nonpeptides as therapeutic agents in this field ([@b45; @b46]) has clearly not been realised. This should be a cautionary tale for those in pharmaceutical companies ([@b138]), in granting agencies ([@b139]) and on study sections ([@b44]) who have strongly promoted the development of nonpeptides over peptides as therapeutic agents. This philosophy led to the abandonment of peptides as potential drugs by Big Pharma almost two decades ago. Clearly, it is now time for Big Pharma to reassess the value of peptides as therapeutic drugs ([@b44]). In this regard, recent progress in the development of peptide drugs ([@b193; @b194]) provides very compelling support for the thesis that peptides are clearly superior to nonpeptides as therapeutic agents, thus bolstering the case for continued support for the design and synthesis of peptides as potential therapies. In this regard, in the OT field, there is an urgent need for functionally selective OT ligands ([@b166]) and for a long lasting OT agonist as a potential therapy for the treatment of autism and other anxiety disorders ([@b139]).

Research uses of peptides
=========================

During the period 1980--2012, over 3000 samples of OT and AVP agonists and antagonists from the Manning laboratory have been and continue to be donated as research tools to over 700 investigators (some multiple times) in the USA and worldwide for their own independent studies. Studies carried out with these donated peptides and with those purchased from commercial suppliers, such as Sigma, Bachem and Peninsula, have resulted in more than 2000 publications by these and other investigators during this period. Examples of studies carried out since 2008 with some of these peptides are available ([@b90; @b117; @b195; @b196; @b197; @b198; @b199; @b200; @b201; @b202; @b203; @b204; @b205; @b206; @b207; @b208; @b209; @b210; @b211; @b212; @b213; @b214; @b215; @b216; @b217; @b218; @b219; @b220; @b221; @b222; @b223; @b224; @b225; @b226; @b227; @b228; @b229; @b230; @b231; @b232; @b233; @b234; @b235; @b236; @b237; @b238; @b239; @b240; @b241; @b242; @b243; @b244; @b245; @b246]).

Research uses of nonpeptides
============================

With the exception of the Sanofi nonpeptide V~2~ antagonist satavaptan, all of the nonpeptide AVP antagonists listed in [Table 9](#tbl9){ref-type="table"} are now available from Tocris or other suppliers. To date, a small number of studies that have utilised the Sanofi V~1a~ antagonist relcovaptan, the Sanofi V~1b~ antagonist nelivaptan and the Sanofi V~2~ antagonist satavaptan have been reported ([@b117; @b118; @b119; @b120; @b125; @b126]) ([Table 9](#tbl9){ref-type="table"}).

The two Merck nonpeptide OT antagonists L-368,899 and L-371,257 and the Pfizer nonpeptide OT agonist Way-267464 shown in [Table 10](#tbl10){ref-type="table"} are all available from Tocris. The Glaxo SmithKline nonpeptide OT antagonist GSK-2211149A (Retosiban) is also available from a number of suppliers. The Pfizer nonpeptide OT antagonist WAY-162720 is not yet commercially available. A number of studies that have utilised some of these nonpeptide ligands as research tools have been reported ([@b138; @b139; @b140; @b141; @b145]) ([Table 10](#tbl10){ref-type="table"}).

Conclusions
===========

In our 2008 review ([@b1]), we examined the status (as of 2007) of both peptide and nonpeptide agonists and antagonists of the OT receptor and of the VP V~1a~, V~1b~ and V~2~ receptors as: (i) research tools and (ii) therapeutic agents. Although the research uses of both peptide and nonpeptide ligands have continued to grow during the intervening 4 years, by contrast, the therapeutic development of nonpeptide AVP and OT antagonists has been drastically curtailed. Merck, Pfizer and Sanofi have all abandoned their nonpeptide programmes. The nonpeptide V~2~/V~1a~ the antagonist, conivaptan and the nonpeptide V~2~ antagonist tolvaptan, which have been approved by the Food and Drug Administration, have not as yet found widespread acceptance in the clinic ([@b113; @b192]). Pfizer has also abandoned its nonpeptide OT agonist programme ([@b44]). It remains to be seen how the Glaxo SmithKline nonpeptide OT antagonist retosiban will fare in its current Phase II clinical trial. All in all, since our 2008 review ([@b1]), interest in the development of nonpeptides as therapeutics has greatly diminished. On the other hand, as noted above, Ferring has a promising V~1a~ agonist ([Table 4](#tbl4){ref-type="table"}) and a promising OT agonist ([Table 1](#tbl1){ref-type="table"}), awaiting clinical development. The design and synthesis of: (i) functionally selective OT peptides and (ii) of a long lasting OT analog as a potential therapy for autism spectrum disorders and other anxiety disorders remain as pressing needs in this field. Both OT and VP peptides and nonpeptides are continuing to be very valuable research tools. In this regard, we have addressed here the issues of the: (i) lack of receptor selectivity, (ii) species differences and (iii) *in vitro--in vivo* differences, all of which need to be taken into account when using a given peptide or nonpeptide ligand as a research tool. Finally, the development of new fluorescent ligands as powerful new tools for localising and characterising OT and VP receptors, which we have presented here, points to the continued usefulness of OT and AVP peptide ligands (agonists, antagonists and fluorescent derivatives) as incisive molecular pharmacological probes.
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